Eisai Gaining Cancer Portfolio In $3.9B MGI Acquisition

Less than two weeks after placating the rumor mill by officially announcing that it was evaluating "strategic alternatives," MGI Pharma Inc. agreed to be acquired by Eisai Co. Ltd. for $41 per share, or about $3.9 billion in cash. (BioWorld Today)